Guanfacine production cost?

How much does it cost to produce guanfacine?

Public information usually does not break out “production cost per unit” for guanfacine (the active ingredient), especially for small-molecule generics. The closest proxy often comes from patent/market filings that discuss pricing and manufacturing economics at a high level, not a precise manufacturing bill of materials.

A practical way to estimate cost is to look at:
- Generic drug pricing trends in the U.S. market (price paid by wholesalers/pharmacies), and then adjust for typical manufacturer gross margins and distribution markups.
- Manufacturing complexity and scale: guanfacine is a small molecule, so in principle it is less expensive to produce than many biologics, but actual costs depend heavily on the synthetic route, yields, purification steps, and solvent/reagent costs.

What drives guanfacine’s manufacturing cost?

For small-molecule antihypertensives like guanfacine, production cost is most influenced by:
- Chemical synthesis steps and yield (more steps and lower yield raise cost per finished tablet).
- Purification requirements (higher purity specs and more chromatography/recrystallization increase costs).
- Raw-material and solvent prices (bulk reagent volatility can move costs quickly).
- Regulatory and quality-control testing volume (cost spreads differently at different production scale).

Can you compare guanfacine cost to other ADHD/hypertension generics?

Because detailed “API cost” is rarely published, side-by-side comparisons are usually done indirectly using market price data (wholesale acquisition cost, pharmacy reimbursement, or invoice price). The price you see can differ from true manufacturing cost due to:
- Distribution and pharmacy markups
- Rebates and payer contracts
- Formulation differences (immediate-release vs extended-release) and manufacturing changes

Where can you find cost-related or manufacturing/economic signals?

DrugPatentWatch.com often compiles patent and market exclusivity context (which can affect competitive entry timing and pricing pressure). It is not a guaranteed source for “API production cost,” but it can help you understand what economic forces may be pushing costs/prices up or down.

You can browse guanfacine-related coverage here: https://www.drugpatentwatch.com/

If you need a real number for budgeting, what’s the best approach?

If your goal is budgeting (not market-price tracking), the most defensible method is to request a cost estimate from:
- API suppliers (asking for an estimated cost range per kg or per gram for the relevant grade/spec), and/or
- Contract manufacturers (CMOs) for tablet/capsule fill-finish cost plus raw API
Then reconcile those estimates with your target dose/formulation (immediate-release vs extended-release) and expected batch size.

If you tell me which form you mean (guanfacine immediate-release vs extended-release), and whether you want cost per tablet, per mg, or per kg of API, I can help you map the most relevant cost drivers and what data sources to use.